Medicines

Transposon TPN-101 LINE-1 programme

Transposon Therapeutics

If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.

WHAT IT IS TRYING TO CHANGE

What the project is doing

Transposon TPN-101 LINE-1 programme is being developed as part of the wider effort to prevent, delay or repair age-related decline.

If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.

The next major checkpoint is whether the human benefit is large and consistent enough to justify a larger study.

Promising signals can disappear in a larger study, and the best dose, long-term safety and real benefit may still be uncertain.

WHERE IT STANDS

Transposon TPN-101 LINE-1 programme is being developed as part of the wider effort to prevent, delay or repair age-related decline.

Likely path

Roughly 3–7 years to broader access if results remain positive.

Why this estimate

A larger confirmatory study and regulatory review would normally still be needed.

Record checked: 2026-08-27

ORIGINAL EVIDENCE

The sources below support the project record. RejuvAccess separately checks whether a practical route is open and worth pursuing.

MAKE IT PERSONAL

Ask RejuvAccess to check the evidence, access route, cost and next step for you.